Form 4: Inozyme Pharma Director Axel Bolte Reports Stock Transactions

Director Axel Bolte reports the acquisition and disposal of Inozyme Pharma (INZY) common stock and stock options on May 15, 2025.

Summary

• On May 15, 2025, Axel Bolte, a director of Inozyme Pharma, Inc. (INZY), engaged in transactions involving the company's common stock and stock options.
• Bolte acquired 152,823 shares of common stock at a price of $0.98 through the exercise of stock options.
• Bolte also acquired 4,407 shares of common stock at a price of $0.98 through the exercise of stock options.
• Following these transactions, Bolte directly owns 423,926 shares of Inozyme Pharma common stock.
• The reported transactions involved fully vested stock options with an exercise price of $0.98, expiring on June 27, 2027.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting insider transactions, which carries a neutral sentiment. It simply reflects the buying and selling activity of a company director.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors regarding the insider's stake in the company.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates

Keywords

Inozyme Pharma, INZY, Axel Bolte, stock options, common stock, director, Form 4, beneficial ownership, securities, transaction